StockData

Avalo Therapeutics vs Inovio Pharmaceuticals

AVTX and INO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AVTX and INO compare

Avalo Therapeutics is the larger company, worth 2.7 times as much as Inovio Pharmaceuticals ($395M against $145M).

Avalo Therapeutics scores higher on the StockData Score (8 against 4 for Inovio Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAVTXINO
Size and price
Market cap$395M$145M
Share price$7.37$1.40
Change, 1 year−50.0%−28.2%
Change, 5 years−99.9%−98.4%
Beta (5Y)2.19−0.03
Employees2327
StockData Score
Total score8 (better)4
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score6 (better)4
Dividend score00
Valuation
P/B0.9× (better)33.1×
FCF yield–−55.8%
Growth
Revenue growth (TTM)–−100%
Revenue growth, 5Y average−61.2%−61.2% (better)
Profitability
Return on equity−36.3% (better)−410%
Financial health
Debt / equity0.000.00
Current ratio19.31 (better)1.00
Altman Z-score4.52 (better)−55.55
Piotroski F-score2 (better)1
Dividends and buybacks
Buyback yield–−26.3%
Shareholder yield0.00% (better)−26.3%
Ownership
Held by institutions135%31.7%
Held by insiders0.71%0.38%
Insider net buying, 12 months−$8.3M–
Short interest, % of float16.7%21.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.